Mr. Hayim Raclaw reports

ALZAI HEALTH CORP. ENTERS INTO MOU WITH QUANTERIX CORPORATION TO ADVANCE EARLY ALZHEIMER'S DISEASE IDENTIFICATION

Alzai Health Corp. has entered into a memorandum of understanding (MOU) with Quanterix Corp., a leader in ultrasensitive biomarker detection and blood-based diagnostic testing, to explore collaboration opportunities aimed at advancing earlier identification and assessment of Alzheimer's disease.

The proposed collaboration is intended to explore opportunities to combine Alzai's AI-driven Alzheimer's disease risk identification technology with Quanterix's LucentAD blood-based biomarkers, with the goal of supporting a more integrated approach to identifying and evaluating individuals at elevated risk for Alzheimer's disease.

By bringing together complementary technologies, the companies intend to explore opportunities with health care providers, health systems and other health care organizations to support earlier patient identification, more targeted diagnostic testing and improved clinical decision-making.

"This collaboration represents an important step in Alzai's strategy to expand the reach and potential applications of our AI-driven disease risk identification technology," said Hayim Raclaw, chief executive officer of Alzai Health. "Quanterix is an established innovator in biomarker detection and Alzheimer's diagnostics. We believe that combining our complementary capabilities has the potential to support a more efficient approach to identifying individuals at elevated risk for Alzheimer's disease and connecting them with appropriate diagnostic evaluation. We look forward to exploring opportunities together to advance Alzheimer's research and patient care."

The MOU is primarily non-binding and any future commercial arrangements will be subject to separate definitive agreements.

About Alzai Health Corp.

Alzai Health is a health care technology company developing non-invasive, AI-driven (artificial intelligence) disease risk identification solutions using routine health care data. The company's proprietary platform is designed to identify individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. Alzai's technology has been validated on large-scale health care data sets and is designed for integration into existing health care infrastructure, including electronic medical record systems, cloud-based environments and enterprise health care platforms.

We seek Safe Harbor.